Dabigatran and Warfarin in Vitamin K Antagonist-Naive and -Experienced Cohorts With Atrial Fibrillation

MD Ezekowitz; L Wallentin; SJ Connolly; A Parekh; MR Chernick; J Pogue; TH Aikens; S Yang; PA Reilly; Gregory Lip; S Yusuf

doi:10.1161/CIRCULATIONAHA.110.973735

Dabigatran and Warfarin in Vitamin K Antagonist-Naive and -Experienced Cohorts With Atrial Fibrillation

MD Ezekowitz, L Wallentin, SJ Connolly, A Parekh, MR Chernick, J Pogue, TH Aikens, S Yang, PA Reilly, Gregory Lip, S Yusuf

Research output: Contribution to journal › Article

148 Citations (Scopus)

Abstract

Background-The comparison of anticoagulants dabigatran and warfarin might be most equitable in vitamin K antagonist (VKA)-naive patients. Methods and Results-Warfarin and 2 doses of dabigatran-110 mg BID (D110) and 150 mg BID (D150)-were compared in a balanced population of VKA-naive (

Original language	English
Pages (from-to)	2246-2253
Number of pages	8
Journal	Circulation
Volume	122
Issue number	22
DOIs	https://doi.org/10.1161/CIRCULATIONAHA.110.973735
Publication status	Published - 1 Nov 2010

Keywords

arrhythmia
stroke
atrial fibrillation
prevention
anticoagulants

Access to Document

10.1161/CIRCULATIONAHA.110.973735

Cite this

@article{a0d81a8bf354446dbd65901a3c3cbbc9,

title = "Dabigatran and Warfarin in Vitamin K Antagonist-Naive and -Experienced Cohorts With Atrial Fibrillation",

abstract = "Background-The comparison of anticoagulants dabigatran and warfarin might be most equitable in vitamin K antagonist (VKA)-naive patients. Methods and Results-Warfarin and 2 doses of dabigatran-110 mg BID (D110) and 150 mg BID (D150)-were compared in a balanced population of VKA-naive (",

keywords = "arrhythmia, stroke, atrial fibrillation, prevention, anticoagulants",

author = "MD Ezekowitz and L Wallentin and SJ Connolly and A Parekh and MR Chernick and J Pogue and TH Aikens and S Yang and PA Reilly and Gregory Lip and S Yusuf",

year = "2010",

month = nov,

day = "1",

doi = "10.1161/CIRCULATIONAHA.110.973735",

language = "English",

volume = "122",

pages = "2246--2253",

journal = "Circulation",

issn = "1524-4539",

publisher = "American Heart Association",

number = "22",

}

TY - JOUR

T1 - Dabigatran and Warfarin in Vitamin K Antagonist-Naive and -Experienced Cohorts With Atrial Fibrillation

AU - Ezekowitz, MD

AU - Wallentin, L

AU - Connolly, SJ

AU - Parekh, A

AU - Chernick, MR

AU - Pogue, J

AU - Aikens, TH

AU - Yang, S

AU - Reilly, PA

AU - Lip, Gregory

AU - Yusuf, S

PY - 2010/11/1

Y1 - 2010/11/1

N2 - Background-The comparison of anticoagulants dabigatran and warfarin might be most equitable in vitamin K antagonist (VKA)-naive patients. Methods and Results-Warfarin and 2 doses of dabigatran-110 mg BID (D110) and 150 mg BID (D150)-were compared in a balanced population of VKA-naive (

AB - Background-The comparison of anticoagulants dabigatran and warfarin might be most equitable in vitamin K antagonist (VKA)-naive patients. Methods and Results-Warfarin and 2 doses of dabigatran-110 mg BID (D110) and 150 mg BID (D150)-were compared in a balanced population of VKA-naive (

KW - arrhythmia

KW - stroke

KW - atrial fibrillation

KW - prevention

KW - anticoagulants

U2 - 10.1161/CIRCULATIONAHA.110.973735

DO - 10.1161/CIRCULATIONAHA.110.973735

M3 - Article

C2 - 21147728

SN - 1524-4539

VL - 122

SP - 2246

EP - 2253

JO - Circulation

JF - Circulation

IS - 22

ER -

Dabigatran and Warfarin in Vitamin K Antagonist-Naive and -Experienced Cohorts With Atrial Fibrillation

Abstract

Keywords

Access to Document

Fingerprint

Cite this